CLINICAL TRIALS, APPROVALS & SAFETY
Currently, our machines are engaged in two clinical trials in the United States. These studies are for submission to the FDA for U.S. FDA clearance, and for adding human use approval in other countries.
To our knowledge, PEMF Systems Inc is the only manufacturer conducting clinical trials in the USA to demonstrate the health benefits and safety of our product. MagnaWave offers the longest most comprehensive warranty available, we also stand behind our PEMF equipment use and safety.
Currently, PEMF Solutions products are not regulated under the FDA. They are to be used as massage like instruments, there is no medical benefit claim currently assigned to their use. In general, PEMF is designed to support overall health and well-being in humans and animals.
In other countries, PEMF has been a mainstream therapy for over 30 years. There have been over 2800 clinical trials completed using many different PEMF devices in many different countries, all with positive results.
THE UNIVERSITY OF MIAMI, MILLER SCHOOL OF MEDICINE STUDY
Pulsed electro-magnetic frequency on chronic knee pain
The purpose of the study is to determine and compare the clinical effectiveness of pulsed electro-magnetic field (PEMF) devices of different power levels in providing a reduction in pain and inflammation as well as increased range of motion and a return to a normal health and activity level.
ONGOING PEMF TRIALS USING OUR DEVICES:
1. Pressure wound healing (bed sores) Veterans Administration Hospital, Long Beach, CA
2. Venous wound healing Henry Ford Hospital, Detroit, MI
MAGNAWAVE PEMF PUBLISHED STUDIES
Published in the SPANISH JOURNAL OF OZONE THERAPY
By: Dr. Vivian Borroto
Study overview; 90 patients with knee pain “resistant to medical treatment” with more than five years of having the diagnosis of osteoarthritis of the knee and 60+ years of age was divided into three groups A. NSAIDS (normal pain meds) B. PEMF and ozone injections (the latest ozone therapy).
C. PEMF 10 sessions each only 6 minutes
Groups B and C had NO “side-affects”, unlike group A, NSAIDS, which experienced gastrointestinal problems and elevated blood pressure.
“Study results for MagnaWave were found to decrease pain, stiffness and improve the quality of life in patients with knee osteoarthritis.”
A. NSAIDS Pills had a 31% reduction
B. MagnaWave PEMF and Ozone 69% reduction
C. MagnaWave PEMF alone 55% reduction
A.NSAIDS 26% improvement
B. MagnaWave PEMF Ozone 85% improvement
C. MagnaWave PEMF 56% improvement
Study 2 – involved 160 patients with lumbar pain. MagnaWave use showed an 82% decrease in pain.